世界のゲノミクス市場

Genomics is transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in house genomics divisions. The aim of this TriMark Publications study is to provide in depth information on the developing market for genomics products and services.

The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets. Forecasts and trends were developed from interviews with industry sources, as well as from an assessment of available and emerging technologies. The report focuses on how researchers are applying new genomic approaches to drug discovery and development, and on how these technologies can be used most effectively and in a high throughput capacity. Case studies analyzing particular applications of genomic technologies to specific disease related research are provided, and future trends and developments are forecasted. Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives and others. These individuals are employed at leading genomics firms or in pharmaceutical and biotechnology companies that either contract with these firms or have developed in house genomics capabilities.

1. Introduction

• 1.1 Statement of Report
• 1.2 Objectives and Goals of Study
• 1.3 Methodology
• 1.4 Executive Summary
  • 1.4.1 Market Drivers
  • 1.4.2 Market Restraints
  • 1.4.3 Market Size and Growth Projections
• 1.5 What Is a Gene?
• 1.6 Gene Expression
• 1.7 Genetic Variability
• 1.8 The Human Genome Project (HGP)
• 1.9 Gene Databases
• 1.10 Sequencing and Resequencing
• 1.11 RNA Interference (RNAi)
• 1.12 DNA Tags

2. Genomics Technology and Industry

• 2.1 The Development of a Genomics Market
  • 2.1.1 Market Size and Growth Projections
  • 2.1.2 The U.S. Genomics Market
• 2.2 DNA Microarray Technology
  • 2.2.1 Biochips
  • 2.2.2 Photolithography
  • 2.2.3 Instrumentation for DNA Microarray Analysis
  • 2.2.4 Lab-on-a-Chip
  • 2.2.5 DNA Microarrays
• 2.3 Applications of DNA Microarrays
  • 2.3.1 DNA Sequence Analysis
  • 2.3.2 Gene Expression Analysis
  • 2.3.3 Effect of DNA Sequence and Gene Expression Monitoring on the Genomics Market
• 2.4 Bioinformatics
• 2.5 Functional Genomics
  • 2.5.1 Gene Knockdown
  • 2.5.2 Protein-Protein Interactions
  • 2.5.3 Bioinformatics
  • 2.5.4 Strategies of Functional Genomics Companies
  • 2.5.5 Frontiers in Functional Genomics
• 2.6 Comparative Genomics
• 2.7 Pharmacogenomics
• 2.8 Proteomics
• 2.9 Structural Genomics
• 2.10 Disease Targets
  • 2.10.1 Paradigm Shift in Drug Development: The Evolution of Targeted Therapies
  • 2.10.2 Personalized Warfarin Therapy

3. How Genomics Is Revolutionizing Healthcare

• 3.1 Pharmaceutical Applications
• 3.2 Diagnostics
• 3.3 Toxicogenomics
• 3.4 The Market for DNA Microarrays
• 3.5 DNA Chip Technology Competition
• 3.6 Expression Profiling
• 3.7 Gene Sequencing-Advantages of Chip Array Technology
• 3.8 Applied Markets for Genomics
• 3.9 Genomics and the Pharmaceutical Companies
• 3.10 Cancer Markets
• 3.11 Agricultural Markets
  • 3.11.1 Plant Genomics
  • 3.11.2 Food Processing
  • 3.11.3 Animal Husbandry

4. Proprietary Applications and Patents

• 4.1 What is Patentable?
• 4.2 Patents and Litigation

5. Business Analysis

• 5.1 Facilitation and Capitalization of the Convergence of Gene Expression Analysis and Proteomics
• 5.2 Competition
• 5.3 Market Opportunities for Functional Genomics
  • 5.3.1 Metabolic Profiling
  • 5.3.2 Anti-Fungal Targets
  • 5.3.3 Nutrition
  • 5.3.4 Crop Production
• 5.4 The Highly-Competitive Nature of the Genomics Industry
  • 5.4.1 First-Generation Biotech
  • 5.4.2 Second-Generation Genomics Companies
  • 5.4.3 Next-Generation DNA Sequencing Companies
• 5.5 Strategic Alliances

• 6.1 Affymetrix, Inc.
• 6.2 Agendia
• 6.3 Agilent Technologies, Inc.
• 6.4 Applied Biosystems Group
• 6.5 Bayer, AG
• 6.6 Biotage
• 6.7 Caliper Life Sciences
• 6.8 Celera Group
• 6.9 Cepheid
• 6.10 CLC bio
• 6.11 Clinical Data, Inc.
• 6.12 CuraGen Corporation
• 6.13 Cytocell Ltd.
• 6.14 diaDexus, Inc.
• 6.15 Enzo Biochem, Inc.
• 6.16 Exiqon A/S
• 6.17 GE Healthcare
• 6.18 Gene Link, Inc.
• 6.19 Gene Logic, Inc.
• 6.20 Genentech, Inc.
• 6.21 Genisphere, Inc.
• 6.22 Genomatix Software, Inc.
• 6.23 Genomic Solutions, Inc.
• 6.24 Gen-Probe, Inc.
• 6.25 Harvard Bioscience, Inc.
• 6.26 Helicos Biosciences Corporation
• 6.27 Human Genome Sciences, Inc.
• 6.28 Illumina, Inc.
• 6.29 Interleukin Genetics
• 6.30 LI-COR Biosciences
• 6.31 Luminex Corporation
• 6.32 Millennium Pharmaceuticals, Inc.
• 6.33 Monogram Biosciences, Inc.
• 6.34 Motorola, Inc.
• 6.35 MWG Biotech AG
• 6.36 Myriad Genetics, Inc.
• 6.37 Nanogen, Inc.
• 6.38 Nuvelo, Inc.
• 6.39 Orchid Cellmark
• 6.40 Pacific Biosciences, Inc.
• 6.41 QIAGEN, Inc.
• 6.42 Roche Diagnostics
• 6.43 Sequenom, Inc.
• 6.44 Third Wave Technologies, Inc.
• 6.45 Verenium Corporation
• 6.46 Visigen Technologies, Inc.
• 6.47 Brief Profiles of Companies Marketing Personalized Genomics Products
  • 6.47.1 23andMe, Inc.
  • 6.47.2 deCODE Genetics, Inc.
  • 6.47.3 Navigenics, Inc.
• 6.48 Brief Profiles of Other Selected Genomics Firms
  • 6.48.1 Aber Genomic Computing
  • 6.48.2 Spotfire, Inc.

7. Genomics Challenges and Growth Factors

• 7.1 Market Drivers
  • 7.1.1 Product Pipeline: Need for More Drug Candidates
  • 7.1.2 Need for Increased Research and Development Productivity
• 7.2 A Genomics Market Bottleneck-Bioinformatics
• 7.3 Strategic Recommendations-Market Opportunities
  • 7.3.1 More Comprehensive Tools Are Needed
  • 7.3.2 Resolving Bottlenecks in Functional Genomics Market
• 7.4 Key Trends of Recent Mergers and Acquisition Deals
• 7.5 Chemogenomics
• 7.6 Pharmacogenomics
• 7.7 Biomarkers
• 7.8 Additional Genomics Market Opportunities

8. Bioinformatics

• 8.1 Types of Data and Bioinformatics Applications
  • 8.1.1 Validated Core Modeling Technology
  • 8.1.2 Broad Applicability
  • 8.1.3 Data Management Compliant with Industry Standards
  • 8.1.4 Open Architecture
  • 8.1.5 Ease of Use
  • 8.1.6 Increased Access
• 8.2 Functions of Informatics Software
  • 8.2.1 Data Management
  • 8.2.2 Transformation of Data into Knowledge
  • 8.2.3 Collaboration Among Researchers
  • 8.2.4 Interface for Online Data Sources
• 8.3 Target Markets for Informatics Software
  • 8.3.1 Pharmaceutical Companies
  • 8.3.2 Biotechnology Companies
  • 8.3.3 Academic and Government Research Institutions
  • 8.3.4 Agricultural, Environmental and Industrial Biotechnology Companies
• 8.4 Products of Bioinformatics
  • 8.4.1 Sequences and Structure of Genes and Proteins
  • 8.4.2 3-D Molecular Structures
  • 8.4.3 Genome Structures and Functions
  • 8.4.4 Bibliographic Data
• 8.5 Bioinformatics Processes
• 8.6 Informatics Tools and Functionalities
  • 8.6.1 Sequence to Structure
  • 8.6.2 Lead Identification and Optimization
  • 8.6.3 Development and Formulation
  • 8.6.4 Improving Materials and Processes in the Chemicals Industry
  • 8.6.5 Other Materials-Based Industries
• 8.7 Role of Bioinformatics in the Value Chain
• 8.8 Bioinformatics Market Segments
  • 8.8.1 Database
  • 8.8.2 Hardware
  • 8.8.3 Software
  • 8.8.4 Bioinformatics Services
• 8.9 Bioinformatics Business Models
  • 8.9.1 Changing Business Models
  • 8.9.2 Selected Business Strategies

Glossary

• Figure 2.1: Major Areas of Functional Genomics and Their Relationship to Bioinformatics and Industry
• Figure 8.1: Role of Bioinformatics in the Biotechnology Value Chain

• Table 2.1: Genomics Sector Global Market Size, 2001 to 2010
• Table 2.2: Companies Marketing DNA Microarray Software
• Table 2.3: Selected Competitors in the DNA Microarray Market
• Table 2.4: Companies Offering DNA Sequencing Products
• Table 2.5: Competitors in the SNP-Genotyping Segment
• Table 2.6: Companies that Market MAQC-tested Gene Expression Microarrays
• Table 2.7: Worldwide Market for Bioinformatics, 2005 to 2010
• Table 2.8: Selected Companies Marketing New Functional Genomics Tools
• Table 3.1: Genomics Pharmaceutical Market Sector Leaders and Promising Newcomers
• Table 3.2: Summary of Assays for HIV Viral Load Testing
• Table 3.3: Global Market for HIV Diagnostic Testing, 2000 to 2012
• Table 3.4: Summary of Molecular Diagnostics Testing
• Table 3.5: Global Market for Molecular Diagnostics Testing, 2000 to 2012
• Table 3.6: U.S. Market for Molecular Diagnostics Testing, 2004 to 2012
• Table 3.7: Applied Markets for Genomics
• Table 3.8: Competitors in the Field of Identity Genomics Testing
• Table 3.9: Opportunities for Molecular-Targeting Therapeutics for Cancer
• Table 3.10: Emerging Companies in the Anti-Cancer Sector
• Table 8.1: Data Source and Bioinformatic Investigations
• Table 8.2: Bioinformatics Activities, Subactivities and Key Players

ご注意：当報告書はDRM（デジタル著作権管理システム）付PDFとなります。ご購入頂いた場合、専用のビューアー（ご購入時無償配布）をPCにインストールして頂き、そのビューアーによってのみPDFの閲覧が可能となります。ファイルのコピー及び内容の抽出は出来ませんのでご注意下さい。尚、プリントアウトは何回でも可能です。ご不明な点につきましてはお問合せください。